CompletedEUCTR 2016-003107-65
Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in Eating disorders
This historical record does not confirm current site availability.
Historical research recordUnited Kingdom
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- United Kingdom
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 82
- Sponsor
- Opiant Pharmaceuticals Inc
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2016-003107-65
- Official title
Show the full official title
Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
United Kingdom
Registry details
Historical country statuses
- United Kingdom — Completed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Opiant Pharmaceuticals Inc.
